Get started
Author

Meghna S. Trivedi

Observed names: M. Trivedi, M.S. Trivedi, Meghna S Trivedi, Meghna Trivedi, Meghna S. Trivedi, Trivedi, M.S., Trivedi, Meghna S.
Observed institutions: NewYork–Presbyterian Hospital, Emory University, Columbia University Irving Medical Center, NYU Langone Health, Herbert Irving Comprehensive Cancer Center, Winship Cancer Institute, Florida Atlantic University, Columbia University, University of Pennsylvania
ORCID: 0000-0002-4831-0492
Observed ORCID: 0000-0002-4831-0492
OpenAlex ID: A5069875127
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
2023 · Kevin Kalinsky, Melissa K. Accordino, et al. · Journal of Clinical Oncology · 210
Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer
2016 · Heather Greenlee, Katherine D. Crew, et al. · Breast Cancer Research and Treatment · 124
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy
2021 · Jason I. Griffiths, Jinfeng Chen, et al. · Nature Cancer · 92
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
2022 · Tizita Z. Zeleke, Qingfei Pan, et al. · Nature Cancer · 78
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
2022 · Kevin Kalinsky, Melissa Kate Accordino, et al. · Journal of Clinical Oncology · 73
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
2020 · Qamar J. Khan, Anne O'Dea, et al. · Journal of Clinical Oncology · 69
Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care
2021 · Tejus Satish, Rohit Raghunathan, et al. · JCO Oncology Practice · 54
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
2024 · Rebecca A. Shatsky, Meghna S. Trivedi, et al. · Nature Medicine · 52
PDF
Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City
2020 · Kevin Kalinsky, Melissa K. Accordino, et al. · Breast Cancer Research and Treatment · 52
PDF
Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ
2017 · Meghna S. Trivedi, Austin M. Coe, et al. · Cancer Prevention Research · 44
Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care
2022 · Rita Kukafka, Samuel Pan, et al. · JAMA Network Open · 40
Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology
2015 · Emily I. Chen, Katherine D. Crew, et al. · PLoS ONE · 39
PDF
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer
2019 · Kathleen Fenn, Matthew Maurer, et al. · Clinical Breast Cancer · 38
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer
2021 · Madeleine B. Hopson, Shing Lee, et al. · Breast Cancer Research and Treatment · 33
PDF
Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools.
2015 · Haeseung Yi, Tong Xiao, et al. · PubMed · 28
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
2021 · Matthew Kearney, Lauren Franks, et al. · Breast Cancer Research and Treatment · 27
PDF
Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer
2023 · Melissa K. Accordino, Shing Lee, et al. · Breast Cancer Research and Treatment · 26
PDF
Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population
2019 · Julia E. McGuinness, Meghna S. Trivedi, et al. · Cancer Genetics · 26
Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women.
2016 · Austin M Coe, William Ueng, et al. · PubMed · 26
Programmed death 1 immune checkpoint inhibitors.
2015 · Meghna S Trivedi, Brianna Hoffner, et al. · PubMed · 26
Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay
2021 · Margaux Wooster, Julia E. McGuinness, et al. · Clinical Breast Cancer · 25
Factors Associated with False Positive Results on Screening Mammography in a Population of Predominantly Hispanic Women
2018 · Julia E. McGuinness, William Ueng, et al. · Cancer Epidemiology Biomarkers & Prevention · 22
Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events
2020 · Dawn L. Hershman, Melissa K. Accordino, et al. · Cancer · 21
PDF
Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
2023 · Kristina A. Fanucci, Mary Jo Pilat, et al. · Cancer Research · 19
Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
2023 · Claudine Isaacs, Rita Nanda, et al. · Cancer Research · 18
Works count: 143
Citation count: 1,541
H-index: 22
I10-index: 34
Year
Topic
Type